Nurix Therapeutics Enrolls First Patient in Bexobrutideg Combination Trial for CLL

BRISBANE, Calif., Oct. 06, 2026 /CourierPR/ -- Nurix Therapeutics, a clinical-stage biopharmaceutical company, has announced the enrollment of the first patient in a Phase 1b/2 clinical trial evaluating the investigational oral Bruton’s tyrosine kinase (BTK) degrader, bexobrutideg, in combination with venetoclax for the treatment of chronic lymphocytic leukemia (CLL). The study, known as NX-5948-203, is part of a global collaboration between Nurix and Roche.

The initial cohort of the trial will focus on patients with relapsed or refractory CLL, with potential expansion to include first-line CLL patients. The strategy involves evaluating bexobrutideg in combination with venetoclax, a standard-of-care therapy for CLL. The study also plans to assess the combination of bexobrutideg with anti-CD20 antibodies, rituximab and obinutuzumab, across multiple cohorts of patients with relapsed or refractory and previously untreated CLL.

Bexobrutideg, currently being evaluated in a broad clinical development program, is part of Nurix’s ongoing efforts to realize the full potential of the drug across B-cell malignancies. The company is also advancing other clinical-stage degraders and degrader antibody conjugates in its pipeline, including NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types.

The Phase 1b/2 clinical trial (NCT07520006) is designed to evaluate the safety, tolerability, and clinical activity of bexobrutideg in combination with venetoclax. Data from the trial are expected to inform future registrational development strategies across lines of therapy in CLL, including evaluating bexobrutideg in combination with the anti-CD20 antibodies rituximab and obinutuzumab across multiple cohorts of patients with relapsed or refractory and previously untreated CLL, and potential expansion into other B-cell malignancies.

Nurix’s commitment to advancing targeted protein degradation medicines is evident in its ongoing clinical trials. The company’s pipeline includes bexobrutideg, a degrader of BTK being co-developed with Roche, and NX-1607, an inhibitor of CBL-B. Additional information about these clinical trials can be found at clinicaltrials.gov.

Forward-looking statements in the press release reflect Nurix’s expectations, assumptions, and projections about the future, including the development of bexobrutideg and the potential of bexobrutideg to serve as a foundational component of future combination regimens. Nurix cautions readers not to place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties. For more information, visit Nurix’s website at www.nurixtx.com.